Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

CONCORD BIOTECH LTD.

NSE : CONCORDBIOBSE : 543960ISIN CODE : INE338H01029Industry : Pharmaceuticals & DrugsHouse : Private

BSE1025.955.35 (+0.52 %)

PREV CLOSE ( ) 1020.60

OPEN PRICE ( ) 1013.80

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 9074

TODAY'S LOW / HIGH ( )987.05 1026.80

52 WK LOW / HIGH ( )987.05 2149.9

NSE1025.105.1 (+0.5 %)

PREV CLOSE( ) 1020.00

OPEN PRICE ( ) 1016.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 202540

TODAY'S LOW / HIGH( ) 987.00 1030.00

52 WK LOW / HIGH ( )987 2150.4

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1984

Management Info

Sudhir Vaid - Chairman Sudhir Vaid - Managing Director

Registered Office

Address 1482-1486 ,Trasad Road,Dholka,
Ahmedabad Dist,
Gujarat-382225

Phone 02714-222604 / 398200

Email complianceofficer@concordbiotech.com

Website www.concordbiotech.com

Registrars Details

MUFG Intime India Pvt Ltd.

C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai

Listing : BSE, NSE

NEWS

20Feb Concord Biotech informs about investor
Pursuant to the relevant provisions of SEBI (Listing Obligations and Dis..

09Feb Clarification Regarding Increase In V
With reference to the BSE''s email L/SURV/ONL/PV/APJ/2025-26/908 dated F..

06Feb Concord Biotech informs about board me
Concord Biotech has informed that the meeting of the Board of Directors..

06Jan Concord Biotech informs about certifi
In compliance with Regulation 74(5) of SEBI (Depositories and Participan..

Financials

Rs. in Millions

	QTR Dec 25	ANNUAL 25
Net Profit	677.83	3729.65
Gross Profit	902.97	4958.76
Operating Profit	1123.03	5507.79
Net Sales	2781.34	12000.87

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

NGL Fine-Chem (BSE) 2146.70 (3.09%)	M.Cap ( in Cr)1326.24
Hester Biosciences (BSE) 1427.90 (4.01%)	M.Cap ( in Cr)1214.70
Haleos Labs (BSE) 1299.00 (3.61%)	M.Cap ( in Cr)392.72
RPG Life Sciences (BSE) 1922.95 (2.35%)	M.Cap ( in Cr)3180.37
Albert David (BSE) 653.15 (6.34%)	M.Cap ( in Cr)372.76

Shareholding Pattern

	PROMOTERS	44.08%
	NON-INSTITUTION	38.77%
	MUTUAL FUNDS/UTI	4.44%
	FI/BANKS/INSURANCE	4.11%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
DSP Healthcare Fund...	2.95
LIC MF Healthcare F...	2.59
SBI Healthcare Opp ...	2.39
Baroda BNP Paribas ...	2.13
Baroda BNP Paribas ...	2.01
Baroda BNP Paribas ...	1.71
Invesco India Manuf...	1.58

Risk Disclosures on Derivatives

Smart Quotes

CONCORD BIOTECH LTD.